Radiomics-based neural network predicts recurrence patterns in glioblastoma using dynamic susceptibility contrast-enhanced MRI.

Journal: Scientific reports
Published Date:

Abstract

Glioblastoma remains the most devastating brain tumor despite optimal treatment, because of the high rate of recurrence. Distant recurrence has distinct genomic alterations compared to local recurrence, which requires different treatment planning both in clinical practice and trials. To date, perfusion-weighted MRI has revealed that perfusional characteristics of tumor are associated with prognosis. However, not much research has focused on recurrence patterns in glioblastoma: namely, local and distant recurrence. Here, we propose two different neural network models to predict the recurrence patterns in glioblastoma that utilizes high-dimensional radiomic profiles based on perfusion MRI: area under the curve (AUC) (95% confidence interval), 0.969 (0.903-1.000) for local recurrence; 0.864 (0.726-0.976) for distant recurrence for each patient in the validation set. This creates an opportunity to provide personalized medicine in contrast to studies investigating only group differences. Moreover, interpretable deep learning identified that salient radiomic features for each recurrence pattern are related to perfusional intratumoral heterogeneity. We also demonstrated that the combined salient radiomic features, or "radiomic risk score", increased risk of recurrence/progression (hazard ratio, 1.61; p = 0.03) in multivariate Cox regression on progression-free survival.

Authors

  • Ka Young Shim
    Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Sung Won Chung
    Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Jae Hak Jeong
    Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Inpyeong Hwang
    Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Chul-Kee Park
    Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Tae Min Kim
    Department of Internal Medicine and Cancer Research Institute, Seoul National University Hospital, Seoul, Korea.
  • Sung-Hye Park
    Department of Pathology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Jae Kyung Won
    Department of Pathology, Seoul National University Hospital, Seoul, Korea.
  • Joo Ho Lee
    Department of Radiation Oncology and Cancer Research Institute, Seoul National University Hospital, Seoul, Korea.
  • Soon-Tae Lee
    Department of Neurology, Seoul National University Hospital, Seoul, Korea.
  • Roh-Eul Yoo
    Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Koung Mi Kang
    Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Tae Jin Yun
    Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Ji-Hoon Kim
  • Chul-Ho Sohn
    Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea; Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
  • Kyu Sung Choi
    Graduate School of Medical Science and Engineering, Korea Advanced Institute for Science and Technology (KAIST), Daejeon, Republic of Korea.
  • Seung Hong Choi
    From the Graduate School of Medical Science and Engineering (K.H.K., S.H.P.) and Department of Bio and Brain Engineering (S.H.P.), Korea Advanced Institute of Science and Technology, Room 1002, CMS (E16) Building, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea; Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea (S.H.C.); Department of Radiology, Seoul National University College of Medicine, and Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea (S.H.C.); and Center for Nanoparticle Research, Institute for Basic Science, Seoul, Republic of Korea (S.H.C.).